Current and Novel Inhibitors of HIV Protease
Gespeichert in:
| Titel: | Current and Novel Inhibitors of HIV Protease |
|---|---|
| Autoren: | Ladislav Machala, Pavlína Řezáčová, Jana Pokorná, Jan Konvalinka |
| Quelle: | Viruses Viruses, Vol 1, Iss 3, Pp 1209-1239 (2009) |
| Verlagsinformationen: | MDPI AG, 2009. |
| Publikationsjahr: | 2009 |
| Schlagwörter: | 0301 basic medicine, 0303 health sciences, HAART, pharmacokinetic boosting, protease inhibitors, Review, alternative inhibitors, Microbiology, QR1-502, 3. Good health, protease dimerization, 03 medical and health sciences, HIV protease, resistance development |
| Beschreibung: | The design, development and clinical success of HIV protease inhibitors represent one of the most remarkable achievements of molecular medicine. This review describes all nine currently available FDA-approved protease inhibitors, discusses their pharmacokinetic properties, off-target activities, side-effects, and resistance profiles. The compounds in the various stages of clinical development are also introduced, as well as alternative approaches, aiming at other functional domains of HIV PR. The potential of these novel compounds to open new way to the rational drug design of human viruses is critically assessed. |
| Publikationsart: | Article Other literature type |
| Sprache: | English |
| ISSN: | 1999-4915 |
| DOI: | 10.3390/v1031209 |
| Zugangs-URL: | https://pubmed.ncbi.nlm.nih.gov/21994591 https://doaj.org/article/70031e2c4d9a450186517972e0a002e9 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185513/figure/f5-viruses-01-01209/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185513 https://www.mdpi.com/1999-4915/1/3/1209/htm http://europepmc.org/articles/PMC3185513 https://www.mysciencework.com/publication/show/current-and-novel-inhibitors-of-hiv-protease https://www.mendeley.com/catalogue/9499cf85-4e59-309a-b5e7-dc427f275337/ |
| Rights: | CC BY |
| Dokumentencode: | edsair.doi.dedup.....8c5fb1fa95035b9b9aa9b68ac3fe5ea9 |
| Datenbank: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | The design, development and clinical success of HIV protease inhibitors represent one of the most remarkable achievements of molecular medicine. This review describes all nine currently available FDA-approved protease inhibitors, discusses their pharmacokinetic properties, off-target activities, side-effects, and resistance profiles. The compounds in the various stages of clinical development are also introduced, as well as alternative approaches, aiming at other functional domains of HIV PR. The potential of these novel compounds to open new way to the rational drug design of human viruses is critically assessed. |
|---|---|
| ISSN: | 19994915 |
| DOI: | 10.3390/v1031209 |